Q-omics provides the consensus-scored NPM1P26 profile across patient tissues and cancer cell-line models. NPM1P26 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NPM1P26 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, NPM1P26 RNA expression shows 17,561 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, HNSC, and ACC as cancer lineages where NPM1P26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPM1P26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPM1P26 survival associations across molecular data types. NPM1P26 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPM1P26 RNA expression–survival associations across cancer types. High NPM1P26 expression shows unfavorable associations in UCEC, SARC, READ and KIRP, but favorable associations in UCS and LAML. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for NPM1P26 RNA expression.
This table summarizes NPM1P26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NPM1P26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPM1P26 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, BLCA, LIHC and CHOL. The HNSC box plot shows higher NPM1P26 RNA expression in tumor versus normal tissue (log2 FC = +0.291, t-test p < 0.001).
This table shows molecular features associated with NPM1P26 in patient tissues and cancer cell lines. In patient samples, NPM1P26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
